Perspective: Will We Ever Know the Optimal Hgb Level in ESRD? by Wish, Jay B.
J Am Soc Nephrol. 2018 Oct; 29(10): 2454–2457.
Published online 2018 Sep 5.
doi: 10.1681/ASN.2018040363: 10.1681/ASN.2018040363
PMCID: PMC6171266
PMID: 30185470
Perspective: Will We Ever Know the Optimal Hgb Level in ESRD?
Jay B. Wish
Division of Nephrology, Indiana University, Indianapolis, Indiana
Corresponding author.
Correspondence: Dr. Jay B. Wish, Division of Nephrology, Indiana University Hospital, 550 North University
Boulevard, Suite 6100, Indianapolis, IN 46202. Email: ude.ui@hsiwj
Keywords: anemia, hemoglobin, ESRD, erythropoietin
Copyright © 2018 by the American Society of Nephrology
The determination of an optimal hemoglobin (Hgb) level in patients with ESRD requires a thorough
assessment of the risks and benefits of the Hgb level itself and the therapy required to achieve it. The 1997
Dialysis Outcomes Quality Initiative anemia treatment guideline  recommended against normalizing
hematocrit/Hgb levels with recombinant human erythropoietin, and rather, it recommended a target
hematocrit level of 33%–36%, which corresponds to a target Hgb level of 11–12 g/dl. Three large
randomized, controlled trials (RCTs) of higher versus lower target Hgb levels in patients with CKD in the
United States treated with erythropoiesis-stimulating agents (ESAs) were published between 1998 and
2009, and they are summarized in Table 1. Although two of these three studies were conducted in patients
with nondialysis CKD, it is not unreasonable to extrapolate their outcomes to the ESKD population. These
RCTs have shown that higher target Hgb levels with ESA therapy are associated with increased vascular
access thrombosis in patients on hemodialysis, increased major cardiovascular events (MACEs), and
increased mortality from preexisting solid tumors. It is intuitive that increased vascular access thrombosis
might be due to increased blood viscosity from the high Hgb levels themselves and that the increased
mortality from preexisting solid tumors might be due to the trophic effects of ESAs. The increased MACE
at higher target Hgb levels is more problematic and could be due to increased blood viscosity, larger ESA
doses required to achieve the higher target Hgb levels, or a combination of the two. Retrospective analyses
of the RCTs have shown that subjects who achieved higher target Hgb levels with low doses of ESAs had
better MACE outcomes than those randomized to lower target Hgb levels who required high doses of
ESAs,  although these analyses are highly confounded by comorbidities that may lead to both ESA
resistance and adverse outcomes. The Food and Drug Administration (FDA), in its 2011 labels for ESAs,
implies a target Hgb range of 10–11 g/dl for patients receiving ESA therapy. The FDA cautions that no
RCT has identified a target Hgb level, ESA dose, or dosing strategy that does not increase the risks of ESA
therapy and recommends that the lowest ESA dose be used to reduce the need for red blood cell
transfusions. Improved outcomes after the new FDA ESA labels and dialysis reimbursement changes in
2011 that led to both lower ESA use and lower Hgb targets cannot differentiate between the two
variables.
It is clear from published RCTs that higher target Hgb levels do not decrease MACEs and actually increase
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them. What would be the rationale for targeting Hgb levels with ESAs higher than the 10–11 g/dl that the
FDA seems to recommend? One would be transfusion avoidance, which is the only benefit of ESAs that
the FDA acknowledges since 2007.  Because transfusions carry their own risk of allergic reactions,
sensitization for future transplant, infection, and iron overload, it would seem prudent to maintain Hgb
levels away from a patient’s transfusion threshold, whatever that might be. Another rationale for targeting
higher Hgb levels is improved quality of life (QOL). In ESA labels before November 2007, the FDA
acknowledged a QOL benefit of therapy on the basis of phase 3 studies that used pre-/post-treatment QOL
questionnaires.  Because RCTs examining high versus low target Hgb levels failed to showed any
consistent QOL benefit at higher Hgb levels, the FDA removed the QOL claim from ESA labels.  It is
notable that the QOL benefit of higher target Hgb levels in the Normal Hematocrit Study  was refuted by a
subsequent analysis.
The most recent 2012 Kidney Disease Improving Global Outcomes (KDIGO) anemia guidelines
recommend initiating ESA therapy when the Hgb falls below 10 g/dl and not maintaining the Hgb level
above 11.5 g/dl. KDIGO acknowledges in a nongraded recommendation that individualization of therapy
will be necessary, because some patients may have improvements in QOL at Hgb concentration above 11.5
g/dl and will be prepared to accept the risks. This recommendation seems to leave the door open for higher
target Hgb levels in an individualized risk versus benefit proposition. Target Hgb levels in selected
guidelines and regulations are summarized in Table 2.
The answer to the question posed in the title of this perspective is that we will probably not know any more
about the optimal target Hgb level in the future than we do now. It is highly unlikely that there will be any
additional RCTs comparing higher versus lower Hgb targets in patients treated with ESAs. Because
targeting a Hgb level is not an exact science in clinical practice, a change in the target Hgb level results in
moving a wide Hgb distribution curve to the right or the left. A move to the left means that more patients
will be transfused on the low Hgb end; a move to the right means that more patients will have MACEs
and/or vascular access thrombosis on the high Hgb end. The goal is to place the Hgb distribution curve in a
position that minimizes the combination of these adverse outcomes. Understanding that evidence-based
recommendations derived from a risk versus benefit analysis are on the basis of population studies is
fundamental to the application of such recommendations to individual patients who may have unique risk
and benefit attributes. Such recommendations are designed as decision-making tools and not as a standard
of care or “one size fits all” approach.
The risk versus benefit proposition of higher target Hgb levels has been on the basis of ESA therapy, which
is associated with high blood levels of the drug and may have off-target effects detrimental to
cardiovascular tissues. Hypoxia inducible factor (HIF) stabilizers, a new class of drugs to treat anemia in
patients with CKD and ESRD, induce a low continuous level of endogenous erythropoietin production in
the kidney and liver, and by also inhibiting hepcidin and improving iron mobilization, they are effective in
raising Hgb levels comparable with those achieved by ESAs.  Whether HIF stabilizers are associated with
fewer MACEs than ESAs at comparable target Hgb levels has yet to be shown, but a more favorable
benefit/risk proposition for HIF stabilizers than for ESAs would reopen the discussion of the optimal Hgb
level in ESRD.
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Table 1.
Large randomized, controlled trials comparing high versus low hemoglobin targets in patients
receiving erythropoiesis-stimulating agents
Study NHS CHOIR TREAT
N 1265 1432 4038
ESA Epoetin alfa Epoetin alfa Darbepoetin alfa
Population Patients on HD with
coexisting HF or CAD, Hct
30%±3% on epoetin alfa
Patients with ND-CKD and
Hgb<11 g/dl not previously
administered ESA
Patients with ND-CKD and
type 2 DM, Hgb<11 g/dl
Hgb target, g/dl 14.0 versus 10.0 13.5 versus 11.3 13.0 versus ≥9.0
Median achieved
Hgb level, g/dl
12.6 versus 10.3 13.0 versus 11.4 12.5 versus 10.6
Primary end point All-cause mortality or
nonfatal MI
All-cause mortality, MI,
hospitalization for HF, or
stroke
All-cause mortality, MI,
myocardial ischemia, HF, and
stroke
Hazard ratio or
relative risk (95%
CI)
1.28 (1.06 to 1.56) 1.34 (1.03 to 1.74) 1.05 (0.94 to 1.17)
Adverse outcome
for higher-Hgb
group
All-cause mortality All-cause mortality Stroke
Hazard ratio or
relative risk (95%
CI)
1.27 (1.04 to 1.54) 1.48 (0.97 to 2.27) 1.92 (1.38 to 2.68)
QOL Better in high-Hgb group
(controversial)
No difference No difference except less
fatigue in high-Hgb group
Comment Increased VA thrombosis in
high-Hgb group
Increased cancer deaths in
high-Hgb group among patients
with prior history of cancer
NHS, Normal Hematocrit Study; CHOIR, Correction of Hemoglobin and Outcomes in Renal Insufficiency; TREAT,
Trial to Reduce Cardiovascular Events with Aranesp Therapy; ESA, erythropoiesis-stimulating agent; HD,
hemodialysis; HF, heart failure; CAD, coronary artery disease; Hct, hematocrit; ND-CKD, nondialysis CKD; Hgb,
hemoglobin; DM, diabetes mellitus; MI, myocardial infarction; 95% CI, 95% confidence interval; QOL, quality of
life; VA, vascular access.
2 3 4
Perspective: Will We Ever Know the Optimal Hgb Level in ESRD? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171266/?report=printable
5 of 6 2/21/2020, 4:06 PM
Table 2.
Hemoglobin targets in selected regulations and guidelines
Source Year Hgb Target, g/dl
NKF-DOQI 1997 11–12
NKF-KDOQI 2001 11–12
NKF-KDOQI 2007 11–12
CMS MAT for United States dialysis units 2008 10–12
US FDA 2011 10–11
KDIGO 2012 10–11.5
CMS MAT for United States dialysis units 2014 10–11
NICE 2015 10–12
Hgb, hemoglobin; NKF, National Kidney Foundation; DOQI, Dialysis Outcomes Quality Initiative; KDOQI, Kidney
Disease Outcomes Quality Initiative; CMS, Centers for Medicare and Medicaid Services; MAT, Measures Assessment
Tool; FDA, Food and Drug Administration; KDIGO, Kidney Disease Improving Global Outcomes; NICE, National
Institute for Health and Care Excellence (United Kingdom).
Corresponds to recommended hematocrit target of 33%–36%.
Articles from Journal of the American Society of Nephrology : JASN are provided here courtesy of American
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